Medical News

Long-term TDF Exposure Elevates Renal Impairment Risk in HIV-infected Adults

There is growing evidence on tenofovir disoproxil fumarate (TDF)-associated nephrotoxicity, however, its use in the management of HIV-1 infection is...

15 Feb, 2019

Email this page
Association of Cardio-metabolic Factors with Mortality among HIV Patients on ART in Malawi

A number of factors including chronic inflammation, immune activation, traditional risk factors and exposure to antiretroviral drugs are reported to...

12 Feb, 2019

Email this page
Epidemiology of Hypertension among HIV-positive versus HIV-negative Individuals in Senegal

Hypertension (HTN) is considered an important cause of morbidity and mortality among people living with HIV (PLHIV) in resource-limited settings. A...

11 Feb, 2019

Email this page
cART May Contribute to Development of MS in HIV-1-infected Patients, Reports a Recent Study

The effects of metabolic syndrome (MS) in HIV-1-infected patients on cardiovascular risk is poorly explored in sub-Saharan Africa. Recently, a cross...

11 Feb, 2019

Email this page

Key Trials

Safety and Efficacy of E/C/F/TAF vs E/C/F/TDF in Treatment Naïve HIV Patients

This trial compares the safety and efficacy of TAF vs TDF co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of...

REALITY: Enhanced Antimicrobial Prophylaxis + ART Improves Survival in Advanced HIV Patients

This study compared the enhanced and standard antimicrobial prophylaxis treatment in patients with advanced HIV disease.

Pre-exposure Chemoprophylaxis with Oral FTC–TDF Prevents HIV Acquisition in Men Who have Sex with Men

Pre-exposure Prophylaxis Initiative (iPrEx) trial was a randomized, double-blind, placebo controlled trial aimed to evaluate the safety and efficacy...

Partners PrEP Study: Oral TDF or TDF–FTC Significantly Reduces the Risk of HIV-1 Acquisition among Heterosexual Men and Women in Serodiscordant Relationships

The Partners PrEP Study is a double-blind, placebo-controlled, phase III clinical trial aimed to assess the safety and efficacy of oral PrEP for the...

Our Publications

Nutshell Series 2: Tuberculosis Infection and Disease

Tuberculosis (TB) is the most common presenting illness and is one of the leading causes of death in people with HIV, particularly in low-income...

Patient Education

Live Healthier, Live Longer

This publication features commonly asked questions by HIV patients regarding HIV therapy, drug side-effects, Do’s and Don’ts while on HIV treatment...

Living with Hope

This publication features common questions which arise in HIV patients mind regarding HIV, diagnosis, transmission, treatment and drug side effects...

Slide Library

HIV - HCV Coinfection

This slide set covers the epidemiology, disease progression and management of HIV-HCV coinfection in the era of directly acting antivirals available...

Email this page
HIV - Pre-exposure Prophylaxis (PrEP): Guidance on PrEP Use

PrEP is the use of an antiretroviral medication by HIV-negative individuals to prevent them from acquiring HIV. These slides give an overview on the...

Email this page
HIV- Post-exposure Prophylaxis (PEP)

Post-exposure prophylaxis (PEP) is the method of preventing exposures of HIV to blood and body fluids and it is considered to be the most important...

Email this page
Isoniazid Preventive Therapy in HIV Infection

HIV is the strongest risk factor for developing tuberculosis (TB) disease in those with latent or new Mycobacterium tuberculosis infection....

Email this page


Which is your preferred 3rd drug in a first-line regimen?
Efavirenz 600
67% (2 votes)
Efavirenz 400
0% (0 votes)
33% (1 vote)
Total votes: 3